- Home
- ESPR vs ENGN Comparison
ESPR vs ENGN Comparison
Compare ESPR & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- ENGN
- Stock Information
- Founded
- ESPR 2008
- ENGN 1999
- Country
- ESPR United States
- ENGN Canada
- Employees
- ESPR N/A
- ENGN N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- ENGN
- Sector
- ESPR Health Care
- ENGN
- Exchange
- ESPR Nasdaq
- ENGN Nasdaq
- Market Cap
- ESPR 305.0M
- ENGN 297.7M
- IPO Year
- ESPR 2013
- ENGN N/A
- Fundamental
- Price
- ESPR $1.50
- ENGN $5.40
- Analyst Decision
- ESPR Buy
- ENGN Buy
- Analyst Count
- ESPR 7
- ENGN 9
- Target Price
- ESPR $6.36
- ENGN $25.22
- AVG Volume (30 Days)
- ESPR 3.9M
- ENGN 52.0K
- Earning Date
- ESPR 03-04-2025
- ENGN 03-10-2025
- Dividend Yield
- ESPR N/A
- ENGN N/A
- EPS Growth
- ESPR N/A
- ENGN N/A
- EPS
- ESPR N/A
- ENGN N/A
- Revenue
- ESPR $332,314,000.00
- ENGN N/A
- Revenue This Year
- ESPR $5.51
- ENGN N/A
- Revenue Next Year
- ESPR $1.42
- ENGN N/A
- P/E Ratio
- ESPR N/A
- ENGN N/A
- Revenue Growth
- ESPR 185.66
- ENGN N/A
- 52 Week Low
- ESPR $1.47
- ENGN $4.42
- 52 Week High
- ESPR $3.94
- ENGN $18.40
- Technical
- Relative Strength Index (RSI)
- ESPR 34.95
- ENGN 39.68
- Support Level
- ESPR $1.47
- ENGN $4.85
- Resistance Level
- ESPR $1.61
- ENGN $5.55
- Average True Range (ATR)
- ESPR 0.13
- ENGN 0.56
- MACD
- ESPR -0.01
- ENGN -0.00
- Stochastic Oscillator
- ESPR 7.69
- ENGN 43.06
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.